BMK vs. APH, BXP, AGY, ANCR, MXCT, NIOX, AMS, BVXP, OXB, and TSTL
Should you be buying Benchmark stock or one of its competitors? The main competitors of Benchmark include Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), Animalcare Group (ANCR), MaxCyte (MXCT), NIOX Group (NIOX), Advanced Medical Solutions Group (AMS), Bioventix (BVXP), Oxford Biomedica (OXB), and Tristel (TSTL). These companies are all part of the "medical" sector.
Alliance Pharma (LON:APH) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
In the previous week, Alliance Pharma and Alliance Pharma both had 1 articles in the media. Benchmark's average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.
Alliance Pharma has higher revenue and earnings than Benchmark. Alliance Pharma is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.
Alliance Pharma presently has a consensus price target of GBX 80.75, suggesting a potential upside of 132.04%. Given Benchmark's higher probable upside, research analysts clearly believe Alliance Pharma is more favorable than Benchmark.
Alliance Pharma has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Benchmark has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Benchmark received 33 more outperform votes than Alliance Pharma when rated by MarketBeat users. Likewise, 72.62% of users gave Benchmark an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
Alliance Pharma has a net margin of -4.15% compared to Alliance Pharma's net margin of -18.96%. Benchmark's return on equity of -2.46% beat Alliance Pharma's return on equity.
71.0% of Alliance Pharma shares are owned by institutional investors. Comparatively, 92.0% of Benchmark shares are owned by institutional investors. 11.7% of Alliance Pharma shares are owned by insiders. Comparatively, 5.8% of Benchmark shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Alliance Pharma beats Benchmark on 9 of the 15 factors compared between the two stocks.
Get Benchmark News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benchmark Competitors List
Related Companies and Tools
